Wuxi Pharmatech, a leading China-based contract research organization for US pharmas and biotechs, priced 13.2 million ADSs at a price of $14 per ADS, a 16.6% premium to the midpoint of its proposed $11 to $13 range. Credit Suisse and JP Morgan were the lead managers on the deal. The stock is expected to begin trading this morning on the NYSE under the ticker "WX."
